Next Article in Journal
Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review
Next Article in Special Issue
mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn’s Disease
Previous Article in Journal
Long Non-Coding RNAs Target Pathogenetically Relevant Genes and Pathways in Rheumatoid Arthritis
Previous Article in Special Issue
Mesenchymal Stem Cells for Perianal Crohn’s Disease
Open AccessArticle

Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs

IBD Unit, Humanitas Research Hospital, 20089 Milan, Italy
Department of Chemistry G. Ciamician, Alma Mater Studiorum University of Bologna, 40100 Bologna, Italy
Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Ioannina School of Health Sciences, 45110 Ioannina, Greece
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy
Author to whom correspondence should be addressed.
Cells 2019, 8(8), 817;
Received: 21 June 2019 / Revised: 24 July 2019 / Accepted: 1 August 2019 / Published: 2 August 2019
Background: Inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD), represent systematic chronic conditions with a deficient intestinal absorption. We first attempt to investigate the serum bile acids (sBAs) profile in a large cohort of IBD patients to evaluate changes under anti-TNF alpha treatment. Methods: Forty CD and 40 UC patients were enrolled and BAs were quantified by high-pressure liquid chromatography-electrospray-tandem mass spectrometry (HPLC-ES-MS/MS). Up to 15 different sBAs concentrations and clinical biomarkers where added to a Principal Component Analysis (PCA) to discriminate IBD from healthy conditions and treatment. Results: PCA allowed a separation into two clusters within CD (biologic-free patients and patients treated with anti-TNF alpha drugs and healthy subjects) but not UC. The first included CD. CD patients receiving anti-TNF alpha have an increase in total sBAs (4.11 ± 1.23 μM) compared to patients not exposed. Secondary BAs significantly increase after anti-TNF alpha treatment (1.54 ± 0.83 μM). Furthermore, multivariate analysis based on sBA concentration highlighted a different qualitative sBAs profile for UC and CD patients treated with conventional therapy. Conclusion: According to our results, anti-TNF alpha in CD restores the sBA profile by re-establishing the physiological levels. These findings indicate that, secondary BAs might serve as an indirect biomarker of the healing process. View Full-Text
Keywords: Crohn’s disease; ulcerative colitis; absorption; bile acids; secondary bile acids Crohn’s disease; ulcerative colitis; absorption; bile acids; secondary bile acids
Show Figures

Figure 1

MDPI and ACS Style

Roda, G.; Porru, E.; Katsanos, K.; Skamnelos, A.; Kyriakidi, K.; Fiorino, G.; Christodoulou, D.; Danese, S.; Roda, A. Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. Cells 2019, 8, 817.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop